当前位置: 首页 > 详情页

The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Department of Neurosurgery, Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou, 215004, Jiangsu, China.
出处:
ISSN:

关键词: Temozolomide Derivative Glioma

摘要:
The aim of this study is to investigate the inhibitory effects of 2T-P400, a derivative of temozolomide (TMZ), on glioma growth. SHG-44 and U373 human glioblastoma cell lines and SHG-44 cell subcutaneous and intracranial xenograft mouse models were used as the model system for these studies. Cell growth was analyzed using MTT assay. For intracranial glioma xenograft model, mouse brains were obtained and made as paraffin section for immunohistochemical staining. Tumor volume was calculated with this formula: tumor volume = length x width(2)/2. The results showed that 2T-P400 or TMZ significantly inhibits cell growth in a concentration dependent manner with the IC50 values of 12.90 +/- 1.05 or 9.73 +/- 2.12 mu g/ml on SHG-44 cell line and 13.12 +/- 0.86 or 10.13 +/- 1.02 mu g/ml on U373 cell line respectively. In SHG-44 cell subcutaneous xenograft model, the tumor volume of 2T-P400 or TMZ treated group was 1,062.12 +/- 204.76 or 803.59 +/- 110.32 mm(3) respectively, which was significantly smaller than that in physiological saline (with volume of 1,968.85 +/- 348.37 mm(3)) treated group. In intracranial xenograft model, the tumor volume of 2T-P400 or TMZ group was 6.12 +/- 1.69 or 5.58 +/- 1.45 mm(3) respectively, significantly smaller than that in physiological saline group of 33.08 +/- 6.88 mm(3). Moreover, polyethylene glycol 400 (PEG400) exhibited no significant tumor growth inhibition. Our results indicated that 2T-P400 posses the same growth inhibitory effect as TMZ on glioblastoma cell lines and the subcutaneously and intracranially transplanted gliomas in xenograft mouse models. It may be a suitable alternate of TMZ for the treatment of glioma via intravenous administration route.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2013]版:
大类 | 3 区 医学
小类 | 3 区 临床神经病学 3 区 肿瘤学
最新[2023]版:
大类 | 2 区 医学
小类 | 3 区 临床神经病学 3 区 肿瘤学
JCR分区:
出版当年[2012]版:
Q2 CLINICAL NEUROLOGY Q2 ONCOLOGY
最新[2023]版:
Q2 CLINICAL NEUROLOGY Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2012版] 出版当年五年平均 出版前一年[2011版] 出版后一年[2013版]

第一作者:
第一作者机构: [1]Department of Neurosurgery, Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou, 215004, Jiangsu, China.
通讯作者:
通讯机构: [1]Department of Neurosurgery, Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou, 215004, Jiangsu, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16461 今日访问量:0 总访问量:871 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院